Monday, 16 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· June 12, 2026

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

View original at finance.yahoo.com
AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results NORTH CHICAGO, Ill., June 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-dur…
Opening lines of the source · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Venetoclax plus obinutuzumab showed positive responses versus obinutuzumab plus chlorambucil including extended progression-free survival, with a demonstrated median time to next treatment of approximately eight years reflecting sustained durability.

    60% confidence
  • The most frequently occurring Grade 3 (≥2%) adverse events in the venetoclax-based combination arm were neutropenia, thrombocytopenia, infusion-related reaction, anemia, febrile neutropenia, pneumonia, and leukopenia.

    60% confidence
  • The nine-year results from the landmark Phase 3 CLL14 trial affirm venetoclax's enduring safety and efficacy, supporting first-line use of venetoclax-based combination regimens in broader CLL patient populations with unprecedented time to next treatment after one year of fixed-duration therapy.

    60% confidence
  • Venetoclax plus obinutuzumab significantly improved PFS compared to chlorambucil plus obinutuzumab, with median PFS of 6.4 years versus 3.2 years (HR 0.50 [95% CI 0.39-0.63], p<0.001) after median follow-up of 9.2 years, and median TTNT of 7.6 years.

    60% confidence